These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1060 related items for PubMed ID: 18515009

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prevention of osteoporosis after breast cancer.
    Reid DM.
    Maturitas; 2009 Sep 20; 64(1):4-8. PubMed ID: 19709826
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Aromatase inhibitors and bone health.
    Bundred NJ.
    Curr Opin Obstet Gynecol; 2009 Feb 20; 21(1):60-7. PubMed ID: 19125005
    [Abstract] [Full Text] [Related]

  • 5. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A.
    Semin Oncol; 2006 Apr 20; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [Abstract] [Full Text] [Related]

  • 6. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE, Body JJ, Gralow JR, Lipton A.
    Cancer Treat Rev; 2008 Apr 20; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
    Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R.
    J Clin Oncol; 2010 Feb 20; 28(6):967-75. PubMed ID: 20065185
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF, Davis J.
    Hawaii Med J; 2007 Jun 20; 66(6):164-6. PubMed ID: 17621865
    [Abstract] [Full Text] [Related]

  • 13. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
    Menopause; 2010 Jun 20; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reducing the risk of bone loss associated with breast cancer treatment.
    Hadji P.
    Breast; 2007 Dec 20; 16 Suppl 3():S10-5. PubMed ID: 18023583
    [Abstract] [Full Text] [Related]

  • 16. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    Yonehara Y, Iwamoto I, Kosha S, Rai Y, Sagara Y, Douchi T.
    J Obstet Gynaecol Res; 2007 Oct 20; 33(5):696-9. PubMed ID: 17845332
    [Abstract] [Full Text] [Related]

  • 17. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA.
    Clin Breast Cancer; 2009 May 20; 9(2):77-85. PubMed ID: 19433387
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.
    Ghazi M, Roux C.
    Best Pract Res Clin Rheumatol; 2009 Dec 20; 23(6):805-11. PubMed ID: 19945692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.